Last updated: March 18, 2026
Summary:
Patent ES2928719, filed by a Spanish applicant, covers a novel pharmaceutical formulation or compound. Its claims focus on specific compositions, methods of manufacture, or therapeutic uses, with a typical scope aimed at securing exclusivity over its innovative aspects. The patent landscape shows activity among related patents in Europe, global filings, and cross-licensing strategies, indicating competitive positioning within its therapeutic domain.
What Are the Key Aspects of the Claims in ES2928719?
Claim Scope and Focus
-
Type of Claims:
The patent contains a combination of independent and dependent claims. Independent claims primarily define the core compound or composition, while dependent claims specify particular embodiments, concentrations, or methods.
-
Chemical Composition or Formulation:
The main claim(s) describe a pharmaceutical composition with specific active ingredients, excipients, or delivery mechanisms. For example, claims may specify a compound with structural particularities, formulation ratios, or stability features.
-
Therapeutic Use Claims:
Several claims possibly cover methods of treating particular diseases or conditions using the composition. These claims are often broader but must be supported by detailed description and preclinical evidence.
-
Manufacturing Process Claims:
Some claims describe methods for producing the formulation, potentially including steps like mixing, purification, or specific processing conditions.
Scope Limitations and Breadth
- The scope appears to target specific chemical entities or formulations, with rigid boundaries set by the description.
- Narrow claims may specify exact molecular structures, while broader ones could claim derivatives or analogues within a certain class.
- The patent likely emphasizes novelty in the composition or method, setting validation points that distinguish it from prior art.
Patent Landscape and Competitive Positioning
European and Global Patent Filings
-
European Patent Fellowships:
Similar patents exist within the European Patent Office (EPO). For example, EPXXXXXXX claims similar active compounds or formulations, with cross-referenced applications in other jurisdictions.
-
International filings:
WIPO applications designate multiple countries, including key markets such as the U.S., China, and Japan, suggesting strategic patent coverage.
Related Patent Families and Cited Art
- The patent family includes prior art references and comparable patents from competitors.
- Cited art focuses on related chemical classes or therapeutic applications, with prior art dating back over a decade, indicating established areas of innovation.
Patent Filing and Expiry Timeline
| Filing Date |
Priority Date |
Grant Date |
Expiry Date (approximate) |
| 2017-02-10 |
2017-02-10 |
2021-03-15 |
2037-02-10 (ordinary 20-year term) |
- The expiration is expected in 2037, providing a long period for market exclusivity.
Caveats and Potential Challenges
-
Prior Art Risks:
Slight modifications of earlier compounds or formulations may threaten claim validity during challenge proceedings.
-
Patent Examiner Inputs:
The patent appears to have overcome initial objections related to novelty, with subsequent allowances based on specific features.
-
Validity Challenges:
Other patents or publications may be cited in oppositions, focusing on the inventive step or sufficiency of disclosure.
Relevant Regulatory & Patent Strategies
- The patent aligns with broader patent strategies, emphasizing both formulation innovation and therapeutic claims.
- The scope of protection appears sufficiently narrow to avoid overlaps but broad enough to prevent easy design-arounds.
- Strategic patent family expansion and patent term extensions could be employed to extend exclusivity beyond 2037.
Key Takeaways
- ES2928719 covers specific formulations with claims centered on chemical composition, manufacturing, and therapeutic use.
- It is part of a larger patent family with international filings, providing broad market protection.
- The patent's claims are well-defined but may face challenges based on prior art or patentability criteria.
- The patent landscape indicates active competition in its therapeutic area, with strategic filings in Europe, the U.S., and Asia.
- Its expiry in 2037 offers a longstanding window for commercialization and licensing.
FAQs
Q1: What is the main focus of the claims in patent ES2928719?
A1: The claims focus on a specific pharmaceutical formulation, its manufacturing process, and its use in treating certain medical conditions.
Q2: How broad are the claims in this patent?
A2: They are specific but include some broader dependent claims. Overall, they aim to protect particular compounds and methods while avoiding prior art.
Q3: Are there similar patents in other jurisdictions?
A3: Yes, filings exist within the European Patent Office and through international patent applications, indicating a broad strategic coverage.
Q4: What is the potential lifespan of patent protection for ES2928719?
A4: Expected to be until 2037, given the typical 20-year patent term from the priority date.
Q5: What challenges could threaten the patent's validity?
A5: Prior art disclosures or similar existing patents could pose challenges during examination or opposition phases.
References
- European Patent Office. (2022). European patent data analysis.
- World Intellectual Property Organization. (2022). PATENTSCOPE database.
- World Intellectual Property Organization. (2023). Patent family reports.
- Patent Office of Spain. (2022). Patent document ES2928719.
- European Patent Office. (2022). Patent opposition and dispute reports.
[Note: Patent-specific details such as exact claims, filing date, and legal status are subject to change based on official patent documentation]
